This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-gp240 antigen scFv to GrB. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the gp240 antigen as well as the biological activity of GrB. The GrB/scFvMEL fusion construct demonstrates impressive antitumor activity and enhances the sensitivity of human melanoma cells to chemotherapy. This immunocytokine was designed for treating melanoma.
Download resources about recombinant antibody development and antibody engineering to boost your research.
There are currently no Customer reviews or questions for ACFP-SH067. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.